MUC-1 Agonist Epitopes for Targeted CTL Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as radiation therapy and chemotherapy, have adverse effects and are not specific or long-lasting, necessitating a need for safer and more targeted therapies for the prevention and treatment of tumors, particularly those associated with MUC-1 antigens.
Innovation Solution
Identification and characterization of anti-tumor cytotoxic T lymphocyte (CTL) epitopes outside the traditional MUC-1 immunogenic regions, with the generation of agonist epitopes that bind strongly to HLA molecules, stimulating a stronger immune response and activating immune cells like dendritic cells to induce cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer treatments (radiation therapy and chemotherapy) are used, then tumor cells can be killed, but adverse effects on the subject occur and the treatment is not specific or long-lasting
Solution Approach 1:
The invention segments the MUC-1 antigen into specific epitopic regions (VNTR and non-VNTR) that can be selectively targeted. By identifying and utilizing specific peptide sequences from MUC-1 that are uniquely expressed on tumor cells, the treatment achieves specificity without affecting normal cells, thereby reducing adverse effects while maintaining anti-tumor efficacy
Solution Approach 2:
The invention introduces agonist epitopes as intermediaries that bridge the gap between the immune system and tumor cells. These modified peptide sequences act as mediators that strongly bind to HLA molecules and activate cytotoxic T lymphocytes specifically against MUC-1 expressing tumor cells, providing targeted therapy without the broad toxicity of traditional treatments
2Duration of action of moving object
If traditional cancer treatments are used, then tumor cells can be killed, but the protective effects are not long-lasting
Solution Approach 1:
The invention employs preliminary action by using agonist epitopes to pre-activate and educate the patient's own cytotoxic T lymphocytes before tumor recurrence can occur. The modified epitopes create a primed immune state that provides long-lasting protective immunity, enabling the immune system to rapidly respond to and eliminate tumor cells that may recur, thereby extending the duration of protective effects
Solution Approach 2:
The invention establishes a feedback mechanism where agonist epitopes continuously stimulate and maintain cytotoxic T lymphocyte activity. The strong binding of modified epitopes to HLA molecules creates a sustained immune response that monitors for and eliminates tumor cells over an extended period, providing long-lasting protective effects while maintaining treatment specificity
3Reliability
If agonist epitopes with strong HLA binding are generated, then a stronger immune response is stimulated, but the complexity of identifying and characterizing epitopes increases
Solution Approach 1:
The invention applies local quality by focusing research and development efforts on specific regions of the MUC-1 antigen (the VNTR and non-VNTR epitopic regions). By concentrating on these particular segments rather than the entire protein, the complexity of epitope identification is reduced while still achieving strong immune responses through targeted agonist epitope development
Data Source
AI summary
Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.